Pharmacokinetic evaluation of ibrexafungerp for the treatment of vulvovaginal candidiasis and beyond.

Expert opinion on drug metabolism & toxicology Pub Date : 2024-08-01 Epub Date: 2024-07-03 DOI:10.1080/17425255.2024.2373095

Gage M Dixon, James S Lewis, George R Thompson

{"title":"Pharmacokinetic evaluation of ibrexafungerp for the treatment of vulvovaginal candidiasis and beyond.","authors":"Gage M Dixon, James S Lewis, George R Thompson","doi":"10.1080/17425255.2024.2373095","DOIUrl":null,"url":null,"abstract":"Introduction: Ibrexafungerp is a new triterpenoid antifungal agent with activity against a variety of fungal species, including Aspergillus spp. and echinocandin-resistant Candida spp.Areas covered: This evaluation will summarize currently available clinical evidence on the use of ibrexafungerp in the treatment/prevention of vulvovaginal candidiasis (VVC) and detail the mechanism of action, pharmacokinetic/pharmacodynamic parameters, and ongoing/latest research involving ibrexafungerp.Expert opinion: The evidence involving the utilization of ibrexafungerp for the treatment of VVC shows that it is superior when compared to placebo and has comparable clinical cure rates when compared with fluconazole. Ibrexafungerp demonstrates reliable coverage against several Candida spp. including echinocandin-resistant strains, Candida auris, and Aspergillus spp. For VVC, a dose of 300 mg (two 150 mg tablets) twice daily is recommended and does not require dose adjustments based on renal or hepatic function. The use of ibrexafungerp outside of VVC is currently under study with several ongoing trials showing promising interim data.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"713-718"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert opinion on drug metabolism & toxicology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17425255.2024.2373095","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/3 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Ibrexafungerp is a new triterpenoid antifungal agent with activity against a variety of fungal species, including Aspergillus spp. and echinocandin-resistant Candida spp.

Areas covered: This evaluation will summarize currently available clinical evidence on the use of ibrexafungerp in the treatment/prevention of vulvovaginal candidiasis (VVC) and detail the mechanism of action, pharmacokinetic/pharmacodynamic parameters, and ongoing/latest research involving ibrexafungerp.

Expert opinion: The evidence involving the utilization of ibrexafungerp for the treatment of VVC shows that it is superior when compared to placebo and has comparable clinical cure rates when compared with fluconazole. Ibrexafungerp demonstrates reliable coverage against several Candida spp. including echinocandin-resistant strains, Candida auris, and Aspergillus spp. For VVC, a dose of 300 mg (two 150 mg tablets) twice daily is recommended and does not require dose adjustments based on renal or hepatic function. The use of ibrexafungerp outside of VVC is currently under study with several ongoing trials showing promising interim data.

查看原文本刊更多论文

用于治疗外阴阴道念珠菌病及其他疾病的伊曲沙芬格普药代动力学评估。

简介：Ibrexafungerp是一种新型三萜类抗真菌剂，对多种真菌，包括曲霉菌属和耐棘白念珠菌属具有活性：本评估将总结目前现有的伊布沙芬格尔普用于治疗/预防外阴阴道念珠菌病（VVC）的临床证据，并详细介绍伊布沙芬格尔普的作用机制、药动学/药效学参数以及正在进行的/最新的研究：专家意见：使用伊布沙芬格尔普治疗VVC的证据显示，与安慰剂相比，伊布沙芬格尔普的疗效更好，与氟康唑相比，伊布沙芬格尔普的临床治愈率与氟康唑相当。伊布沙芬对多种念珠菌属（包括棘白念珠菌耐药菌株、白色念珠菌属和曲霉菌属）具有可靠的抑制作用。对于 VVC，建议剂量为 300 毫克（两片 150 毫克），每天两次，无需根据肝肾功能调整剂量。目前正在对伊曲沙芬格普在VVC以外的用途进行研究，几项正在进行的试验显示了良好的中期数据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert opinion on drug metabolism & toxicology

自引率

0.00%

发文量